Literature DB >> 15178443

Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis.

Samuel Ko1, Kent-Man Chu, John M Luk, Bonnie W Wong, Siu-Tsan Yuen, Suet-Yi Leung, John Wong.   

Abstract

Gastric cancer remains the second leading cause of cancer deaths worldwide. Patients usually present late with local invasion or metastatic diseases. The present study investigated the expression level of liver-intestine cadherin (LI-cadherin) by RT-PCR and its correlation with clinicopathological data in 71 pairs of tumor and non-cancerous gastric mucosa. Protein expression level of LI-cadherin was determined by Western blotting and immunohistochemistry. The mRNA of LI-cadherin was highly expressed in tumor as compared to non-cancerous mucosa. Lymph node metastasis was significantly associated with the expression of LI-cadherin (p=0.038). On multivariate analysis, T staging and LI-cadherin expression were found to be independent factors associated with lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178443     DOI: 10.1016/j.bbrc.2004.04.197

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Altered expression of a Li-cadherin in gastric cancer and intestinal metaplasia.

Authors:  Weiguo Dong; Qiongfang Yu; Yu Xu
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

2.  Knockdown of Li-cadherin increases metastatic behaviors of LoVo cells.

Authors:  Qiong-Fang Yu; Wei-Guo Dong; Jian-Lin Ren
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.

Authors:  Reiko Ito; Naohide Oue; Kazuhiro Yoshida; Kyoko Kunimitsu; Hirofumi Nakayama; Kei Nakachi; Wataru Yasui
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

4.  Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway.

Authors:  Jin Wang; Wei-Ming Kang; Jian-Chun Yu; Yu-Qin Liu; Qing-Bin Meng; Zhan-Jiang Cao
Journal:  Cancer Biol Ther       Date:  2013-01-08       Impact factor: 4.742

5.  Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.

Authors:  Andreas Weimann; Anja Rieger; Mathias Zimmermann; Monica Gross; Peter Hoffmann; Hortense Slevogt; Lars Morawietz
Journal:  Virchows Arch       Date:  2010-09-16       Impact factor: 4.064

6.  Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma.

Authors:  Ren-Yin Chen; Juan-Juan Cao; Juan Chen; Jian-Ping Yang; Xiao-Bo Liu; Guo-Qiang Zhao; Yu-Feng Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Phenotypic classification of gastric signet ring cell carcinoma and its relationship with clinicopathologic parameters and prognosis.

Authors:  Meng-Meng Tian; Ai-Lian Zhao; Zhong-Wu Li; Ji-You Li
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

Review 8.  Involvement of liver-intestine cadherin in cancer progression.

Authors:  Masaaki Takamura; Satoshi Yamagiwa; Yasunobu Matsuda; Takafumi Ichida; Yutaka Aoyagi
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

9.  Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Authors:  Ling Xiao Liu; Nikki P Lee; Vivian W Chan; Wen Xue; Lars Zender; Chunsheng Zhang; Mao Mao; Hongyue Dai; Xiao Lin Wang; Michelle Z Xu; Terence K Lee; Irene O Ng; Yangchao Chen; Hsiang-fu Kung; Scott W Lowe; Ronnie T P Poon; Jian Hua Wang; John M Luk
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

10.  Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.

Authors:  Zhaohu Lin; Chao Zhang; Meifang Zhang; Danqing Xu; Yanfen Fang; Zheng Zhou; Xiaolong Chen; Ning Qin; Xiongwen Zhang
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.